Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-Null Mice

Circulation Research

Volumn 104, Issue 10, 2009, Pages 1160-1168

  She, Zhi Gang ^a,b   Zheng, Wei ^a   Wei, Yu Sheng ^a   Chen, Hou Zao ^a   Wang, Ai Bing ^a   Li, Hong Liang ^a   Liu, Guang ^a   Zhang, Ran ^a   Liu, Jin Jing ^a   Stallcup, William B ^b   Zhou, Zhongjun ^c   Liu, De Pei ^a   Liang, Chih Chuan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atherosclerosis; Macrophages; Paraoxonase cluster; Plaques stability

Indexed keywords

APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; COLLAGEN; GELATINASE B; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; CCL2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL CHROMOSOME; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL CHROMOSOME; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOAM CELL; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE REPRESSION; HEART PROTECTION; IN VITRO STUDY; INFLAMMATION; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; SMOOTH MUSCLE FIBER; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; ATHEROSCLEROSIS; BLOOD; DISEASE MODEL; FAT INTAKE; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; MULTIGENE FAMILY; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY;

ANIMALS; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CHEMOKINE CCL2; DIETARY FATS; DISEASE MODELS, ANIMAL; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIGENE FAMILY; OXIDATION-REDUCTION;

EID: 66949179058     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.192229     Document Type: Article

References (37)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104: 503-516.
3. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17:1859-1867.
4. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
5. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
6. Galis ZS. Vulnerable plaque: the devil is in the details. Circulation. 2004;110:244-246.
7. Schwartz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007;27:705-713.
8. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated para-oxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
9. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
10. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000; 275:17527-17535.
11. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106:484-490.
12. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775-2779.
13. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
14. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276:44444-44449.
15. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem. 2006; 281:29491-29500.
16. Leus FR, Zwart M, Kastelein JJ, Voorbij HA. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis. 2001;154: 641-649.
17. Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation. 2007;115:2055-2064.
18. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542-547.
19. Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman AM, Lusis AJ, Reddy ST. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res. 2007;100:1200-1207.
20. Reddy ST, Devarajan A, Bourquard N, Shih D, Fogelman AM. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol. 2008;19:405-408.
21. Webb NR. Getting to the core of atherosclerosis. Nat Med. 2008;14: 1015-1016.
22. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649-1654.
23. Gao J, Wei Y, Huang Y, Liu D, Liu G, Wu M, Wu L, Zhang Q, Zhang Z, Zhang R, Liang C. The expression of intact and mutant human apoAI/CIII/AIV/AV gene cluster in transgenic mice. J Biol Chem. 2005; 280:12559-12566.
24. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res. 1995; 36:2320-2328.
25. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008;80:191-199.
26. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, Takeshita A. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2001;103:2096-2101.
27. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97:1630-1639.
28. Jiang ZY, Hunt JV, Wolff SP. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem. 1992;202:384-389.
29. Dwivedi A, Anggard EE, Carrier MJ. Oxidized LDL-mediated monocyte adhesion to endothelial cells does not involve NFkappaB. Biochem Biophys Res Commun. 2001;284:239-244.
30. Rader DJ, Pure E. Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell? Cell Metab. 2005;1:223-230.
31. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000;191:189-194.
32. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
33. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet. 2000;355:19-24.
34. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: an overview. Clin Cardiol. 1991;14: I1-I16.
35. Palombo D, Maione M, Cifiello BI, Udini M, Maggio D, Lupo M. Matrix metalloproteinases. Their role in degenerative chronic diseases of abdominal aorta. J Cardiovasc Surg (Torino). 1999;40:257-260.
36. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 2006;116:59-69.
37. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993-998.